Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors.

London CA, Acquaviva J, Smith DL, Sequeira M, Ogawa LS, Gardner HL, Bernabe LF, Bear MD, Bechtel SA, Proia DA.

Clin Cancer Res. 2018 Dec 15;24(24):6396-6407. doi: 10.1158/1078-0432.CCR-18-0703. Epub 2018 Aug 31.

2.

Oncoplastic breast reduction in conservative surgery.

Rancati A, Angrigiani C, Dorr J, Acquaviva J, Nava MB, Catanuto G, Rocco N, Rancati A, Curutchet P.

Minerva Chir. 2018 Jun;73(3):334-340. doi: 10.23736/S0026-4733.18.07660-5. Epub 2018 Feb 21. Review.

PMID:
29471621
3.

HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors.

Proia DA, Smith DL, Zhang J, Jimenez JP, Sang J, Ogawa LS, Sequeira M, Acquaviva J, He S, Zhang C, Khazak V, Astsaturov I, Inoue T, Tatsuta N, Osman S, Bates RC, Chimmanamada D, Ying W.

Mol Cancer Ther. 2015 Nov;14(11):2422-32. doi: 10.1158/1535-7163.MCT-15-0455. Epub 2015 Aug 13.

4.

The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.

Smith DL, Acquaviva J, Sequeira M, Jimenez JP, Zhang C, Sang J, Bates RC, Proia DA.

Target Oncol. 2015 Jun;10(2):235-45. doi: 10.1007/s11523-014-0329-6. Epub 2014 Aug 1.

5.

FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.

Acquaviva J, He S, Zhang C, Jimenez JP, Nagai M, Sang J, Sequeira M, Smith DL, Ogawa LS, Inoue T, Tatsuta N, Knowles MA, Bates RC, Proia DA.

Mol Cancer Res. 2014 Jul;12(7):1042-54. doi: 10.1158/1541-7786.MCR-14-0004. Epub 2014 Apr 30.

6.

mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis.

Acquaviva J, He S, Sang J, Smith DL, Sequeira M, Zhang C, Bates RC, Proia DA.

Mol Cancer Res. 2014 May;12(5):703-13. doi: 10.1158/1541-7786.MCR-13-0605. Epub 2014 Feb 19.

7.

Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.

Acquaviva J, Smith DL, Jimenez JP, Zhang C, Sequeira M, He S, Sang J, Bates RC, Proia DA.

Mol Cancer Ther. 2014 Feb;13(2):353-63. doi: 10.1158/1535-7163.MCT-13-0481. Epub 2014 Jan 7.

8.

Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.

Proia DA, Zhang C, Sequeira M, Jimenez JP, He S, Spector N, Shapiro GI, Tolaney S, Nagai M, Acquaviva J, Smith DL, Sang J, Bates RC, El-Hariry I.

Clin Cancer Res. 2014 Jan 15;20(2):413-24. doi: 10.1158/1078-0432.CCR-13-2166. Epub 2013 Oct 30.

9.

Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes.

Friedland JC, Smith DL, Sang J, Acquaviva J, He S, Zhang C, Proia DA.

Invest New Drugs. 2014 Feb;32(1):14-24. doi: 10.1007/s10637-013-9971-6. Epub 2013 May 18.

10.

Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.

Sang J, Acquaviva J, Friedland JC, Smith DL, Sequeira M, Zhang C, Jiang Q, Xue L, Lovly CM, Jimenez JP, Shaw AT, Doebele RC, He S, Bates RC, Camidge DR, Morris SW, El-Hariry I, Proia DA.

Cancer Discov. 2013 Apr;3(4):430-43. doi: 10.1158/2159-8290.CD-12-0440. Epub 2013 Mar 26.

11.

Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.

He S, Zhang C, Shafi AA, Sequeira M, Acquaviva J, Friedland JC, Sang J, Smith DL, Weigel NL, Wada Y, Proia DA.

Int J Oncol. 2013 Jan;42(1):35-43. doi: 10.3892/ijo.2012.1698. Epub 2012 Nov 14.

12.

Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.

Acquaviva J, Smith DL, Sang J, Friedland JC, He S, Sequeira M, Zhang C, Wada Y, Proia DA.

Mol Cancer Ther. 2012 Dec;11(12):2633-43. doi: 10.1158/1535-7163.MCT-12-0615. Epub 2012 Sep 25.

13.

Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.

Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, Zhou D, Inoue T, Tatsuta N, Sang J, Ye S, Acquaviva J, Ogawa LS, Wada Y, Barsoum J, Koya K.

Mol Cancer Ther. 2012 Feb;11(2):475-84. doi: 10.1158/1535-7163.MCT-11-0755. Epub 2011 Dec 5.

14.

Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme.

Jun HJ, Acquaviva J, Chi D, Lessard J, Zhu H, Woolfenden S, Bronson RT, Pfannl R, White F, Housman DE, Iyer L, Whittaker CA, Boskovitz A, Raval A, Charest A.

Oncogene. 2012 Jun 21;31(25):3039-50. doi: 10.1038/onc.2011.474. Epub 2011 Oct 24.

15.

Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.

Acquaviva J, Jun HJ, Lessard J, Ruiz R, Zhu H, Donovan M, Woolfenden S, Boskovitz A, Raval A, Bronson RT, Pfannl R, Whittaker CA, Housman DE, Charest A.

Cancer Res. 2011 Dec 1;71(23):7198-206. doi: 10.1158/0008-5472.CAN-11-1514. Epub 2011 Oct 10.

16.

[Recommendations for the diagnosis and management of allergic rhinitis (excluding epidemiology and physiopathology) --long text].

Braun JJ, Devillier P, Wallaert B, Rancé F, Jankowski R, Acquaviva JL, Beley G, Demoly P; Société Française d’Allergologie; Société Française d’Oto-Rhino-Laryngologie et de Chirurgie de la Face et du Cou; Société Française de Documentation et de Recherche en Médecine Générale; Société Française de Pédiatrie.

Rev Mal Respir. 2010 Nov;27 Suppl 2:S79-112. doi: 10.1016/S0761-8425(10)70012-7. French. No abstract available.

PMID:
20889026
17.

Cooperation between deficiencies of IRF-4 and IRF-8 promotes both myeloid and lymphoid tumorigenesis.

Jo SH, Schatz JH, Acquaviva J, Singh H, Ren R.

Blood. 2010 Oct 14;116(15):2759-67. doi: 10.1182/blood-2009-07-234559. Epub 2010 Jun 28.

18.

Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis.

Zhu H, Acquaviva J, Ramachandran P, Boskovitz A, Woolfenden S, Pfannl R, Bronson RT, Chen JW, Weissleder R, Housman DE, Charest A.

Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2712-6. doi: 10.1073/pnas.0813314106. Epub 2009 Feb 5.

19.

The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer.

Acquaviva J, Wong R, Charest A.

Biochim Biophys Acta. 2009 Jan;1795(1):37-52. doi: 10.1016/j.bbcan.2008.07.006. Epub 2008 Aug 3. Review.

PMID:
18778756
20.

IRF-4 functions as a tumor suppressor in early B-cell development.

Acquaviva J, Chen X, Ren R.

Blood. 2008 Nov 1;112(9):3798-806. doi: 10.1182/blood-2007-10-117838. Epub 2008 Aug 19.

21.

[Acute intermittent porphyria in 2 Moroccan families. Clinical and biological study].

Aquaron R, Zarrouck K, el Boussaki A, Acquaviva JE.

Rev Med Interne. 1996;17(6):477-81. Review. French.

PMID:
8758536
22.

Exacerbation of panic disorder during propranolol therapy.

Levinson DF, Acquaviva J.

J Clin Psychopharmacol. 1988 Jun;8(3):193-5.

PMID:
3379142

Supplemental Content

Loading ...
Support Center